Tisagenlecleucel,axicabtagene ciloleucel
daiichi sankyo,novartis ,gilead
['lysa']
axic-cel ; second-line therapy for lbcl in bmt-ineligible patients: primary analysis of alycante, a phase 2 lysa study #cart #bmtsm #cartcell #immunotherapy #tcellrx #ican #crs #cartcells #celltherapy #gene #genetherapy #ash22 #ash2022 
Cellular Therapy Program @ KFSHRC KSA #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CARTTherapy